A Q&A With A Venture Capitalist/Genetic Medicines Executive

By Ben Comer, Chief Editor, Life Science Leader

Sung You, managing partner at PBM Capital and chief business and strategy officer at SalioGen Therapeutics, a preclinical genetics medicines company, knows the importance of telling a good story. Formerly a VP at Morgan Stanley’s healthcare investment banking group, You reviews some 1,000 company fundraising proposals each year for PBM Capital, a “stage-agnostic” VC firm that benefits, says You, from not putting external investment dollars on the line. PBM Capital funding comes exclusively from internal resources and can range from as little as $500,000 in initial investment funds, to more than $30 million. By eschewing outside investors, PBM Capital can jump in earlier and take bigger risks.